ALK-Abelló A/S (ALK-B.CO) Stock Analysis & Winston Score

ALK-Abelló is a Danish pharmaceutical company that makes allergy treatments. Its main products are allergy immunotherapy medicines — these are treatments that help people's immune systems stop overreacting to things like pollen, dust mites, and pet dander. The company sells to doctors, clinics, and hospitals across Europe, North America, and other markets worldwide. ALK-Abelló earns money by selling prescription allergy immunotherapy products, including both injections and dissolvable tablets that patients take under the tongue. It operates primarily in Europe but has been expanding in North America and Asia. The company holds a strong competitive position because allergy immunotherapy is a specialized field with high regulatory barriers, and ALK-Abelló has decades of clinical data and established doctor relationships. The key growth driver is the shift toward convenient tablet-based treatments, which are easier for patients than injections, though pricing pressure from generic competitors and reimbursement decisions by health insurers remain ongoing risks.